Medical Only (Private)

Reimbursed Care Access in Ghana

Ghana regulates psychedelic and psychotropic substances under the Narcotics Drugs (Control, Enforcement and Sanctions) Law, 1990 (PNDCL 236) and through the Narcotics Control Commission; classical psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X, ibogaine, ayahuasca constituents) are treated as controlled/illegal outside of tightly controlled contexts, while ketamine is available and routinely used as an anaesthetic within hospitals. There is no public record of registration or routine clinical/insured use of newer regulated psychedelic medicines (e.g., esketamine/Spravato) in Ghana at national level; access to psychedelic compounds for psychiatry would be limited to hospital anaesthetic use (ketamine), approved clinical research, or exceptional authorised importation under licence. [https://ghanalegal.com/laws_subdomain/acts/id/538/narcotic-drugs-control_-enforcement-and-sanctions-law/|PNDCL 236] [https://www.mint.gov.gh/agencies/narcotic-control-board/|Narcotics Control Commission (Ghana)]

Psilocybin

Strictly Illegal

Currently classified as a strictly controlled substance under Ghana’s Narcotic Drugs (Control, Enforcement and Sanctions) Law, 1990 (PNDCL 236), with no authorized medical use outside of approved clinical research. Possession, cultivation, importation or distribution of psilocybin-containing materials is criminalised and enforced by the national narcotics authority. # #

MDMA

Strictly Illegal

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Enforcement and prosecution are handled under PNDCL 236 and by the Narcotics Control Commission. # #

Esketamine

Not Registered / No Public Medical Program

Esketamine (marketed as Spravato in jurisdictions where it is authorised) is not part of Ghana’s routine registered psychiatric pharmacopoeia and there is no public record of a national registration or national reimbursement program for esketamine in Ghana; Ghana’s regulatory and narcotics frameworks focus on controlling illicit psychotropic/narcotic substances while the Food and Drugs Authority and health facilities regulate therapeutic product approvals and hospital supplies. Ketamine (racemic) is available in Ghana for anaesthesia and procedural sedation in hospitals, but esketamine as a marketed intranasal psychiatric product is not documented in public Ghanaian regulatory listings or guidance (no publicly available approval/registration record). Ketamine’s use in psychiatry (e.g., off‑label infusions for depression) would be off‑label and largely private/out‑of‑pocket where provided; it is not reimbursed as an approved national psychiatric drug. For context on esketamine’s regulatory status elsewhere and its specialised REMS/supervised delivery requirements, see the manufacturer/regulatory databases in jurisdictions where it is approved. # #

Ketamine

Off-label Medical (Anaesthetic; limited psychiatric off-label use)

Ketamine is an established, legally procured anaesthetic and analgesic in Ghanaian hospitals and emergency services; it is widely stocked as an injectable anaesthetic for surgical, emergency and procedural use and is subject to prescription/controlled distribution in clinical settings. Hospital and clinical use for anaesthesia is accepted and regulated by pharmacy/hospital procurement and the national health system; private clinics and public hospitals procure ketamine through registered pharmaceutical suppliers. Off‑label psychiatric uses (e.g., sub‑anaesthetic infusions for treatment‑resistant depression) do occur internationally and may be provided privately in Ghana but are not a nationally reimbursed, standard psychiatric indication and would typically be out‑of‑pocket and subject to local hospital policy and prescriber judgement. The broader narcotics framework (PNDCL 236) and the Narcotics Control Commission govern illicit diversion and criminal penalties, while the Food and Drugs Authority and pharmacy regulatory bodies oversee legal procurement and distribution for medical use. # # #

DMT

Strictly Illegal

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT and DMT‑containing preparations (including ayahuasca in which DMT is an active constituent) are treated as controlled; unregulated possession, importation or distribution is subject to criminal sanction under PNDCL 236. # #

5-MeO-DMT

Strictly Illegal

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession, distribution and use are criminal offences outside authorised scientific/clinical trials. # #

Ibogaine

Strictly Illegal

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no recognised, reimbursed medical program for ibogaine treatment in Ghana; use outside approved research is criminalised. # #

Ayahuasca

Strictly Illegal

Currently classified as a strictly controlled substance under national drug scheduling laws when its active components (notably DMT) are present; there is no authorised religious exemption, commercial distribution or reimbursed medical program for ayahuasca in Ghana outside of approved clinical research. Use, importation or distribution of DMT‑containing brews is subject to criminal enforcement under PNDCL 236. # #

Mescaline

Strictly Illegal

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti are controlled in practice and unauthorised possession or distribution is criminalised under Ghana’s narcotics law. # #

2C-X

Strictly Illegal

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Designer phenethylamines in the 2C family are treated as controlled or illegal substances under PNDCL 236 and related enforcement provisions. # #